Abstract: Described herein is a genetically modified plant or non-human animal having reduced expression of an endogenous target gene.

Abstract: Devices and methods for mass spectroscopic analysis of particles are disclosed herein. An example device includes: a first irradiation unit configured to irradiate a particle with electromagnetic radiation to cause components of the particle to detach from the particle. The example device further includes a second irradiation unit configured to irradiate substantially simultaneously i) at least a part of the detached components, and optionally a residual core of the particle, with a first beam of electromagnetic radiation the first beam of electromagnetic radiation exhibiting a first intensity, and ii) at least a part of the residual core, of the particle with a second beam of electromagnetic radiation. The second beam of electromagnetic radiation exhibiting a second intensity, which is preferably larger than the first intensity. The example device further includes a mass spectrometer comprising an ion source region, a first detection channel, and optionally a second detection channel.

Abstract: The present invention relates to a kit-of-parts comprising at least one mitochondrial uncoupler and at least one cationic amphiphilic drug and its use in medicine. The invention further relates to a pharmaceutical composition comprising at least one mitochondrial uncoupler and at least one cationic amphiphilic drug for use in medicine. Moreover, the invention is directed to the kit-of-parts and the pharmaceutical composition for use in the treatment of cancer, in particular glioma, pancreatic cancer, small cell lung cancer, metastatic prostate cancer, liver cancer and triple-negative breast cancer.

Abstract: The present invention relates to a method for detecting a nucleic acid construct or part thereof and/or for detecting the expression product of the nucleic acid construct or part thereof, wherein the method comprises inserting a nucleic acid construct or part thereof into an intron or a synthetic intron, wherein the nucleic acid construct comprises certain defined structures according to the present invention. The present invention also relates to the various uses of the method described herein, to the nucleic acid construct, a vector comprising said nucleic acid construct, a cell comprising said nucleic acid construct and/or said vector, and a respective kit.

Abstract: The present invention provides herpesviruses, such as EBV, which lack at least one viral miRNA. Such herpesviruses lacking at least one viral miRNA are advantageously not capable of packaging their genome into the capsid, thereby producing HVLPs, which are substantially free of their herpesvirus genome or the nucleic acid molecule encoding the proteinaceous part of the HVLP and viral miRNA. Such HVLPs may be used as vaccine.

Abstract: The invention relates to a device (1) and an according method for optoacoustic imaging of an object. The device (1) comprising an irradiation unit for irradiating a region of interest (3) of the object with electromagnetic radiation (6), in particular light, and a detection unit (9) for detecting acoustic, in particular ultrasonic, waves generated in the region of interest (3) of the object upon irradiation with the electromagnetic radiation (6), wherein the detection unit (9) is configured to detect the acoustic waves at one or more point-like detection locations, which are located outside of the region of interest (3) of the object. The point-like detection locations can be given by, e.g., focus points (19) of acoustic detection elements (23), point-like detection elements or point-like or pinhole apertures. The invention allows for improved and reliable optoacoustic imaging, in particular in view of dermatology applications.

Abstract: The present invention discloses a method for assessing the capacity of a substance to treat or prevent hepadnavirus infection. A reporter virus carrying genetic information for a first fragment of a recombinase and a reporter cell expressing a second fragment of the recombinase are used. When the reporter virus infects the reporter cell, the two fragments of the recombinase associate and excise a stop cassette that is flanked by two recombination sites and blocks the expression of a reporter gene. Accordingly, the present invention relates to a method of assessing the capacity of a substance to treat or prevent hepadnavirus infection, a hepadnavirus comprising a nucleic acid encoding a first fragment of a recombinase and a mammalian hepatocyte or hepatoma cell comprising a nucleic acid encoding a second fragment of a recombinase and a nucleic acid comprising a stop cassette flanked by two recombination sites fused to a reporter gene.

Abstract: The present invention relates to a method for preparing a bactericidal phage vector, (pharmaceutical) compositions comprising such phage vectors, also for use in treating diseases, particularly those caused by (antimicrobial resistance) bacterial cells.

Abstract: The present invention relates to systems, methods and fluorophores for real-time multicolor shortwave infrared fluorescence imaging. The systems and methods of the present invention further relate to real-time multi-color in vivo SWIR imaging systems employing high-power excitation sources in combination with state of the art InGaAs SWIR detectors and SWIR illuminated fluorophores.

Abstract: The present invention relates to systems, methods and fluorescent polypeptide for real-time multicolor shortwave infrared fluorescence imaging. The systems and methods of the present invention further relate to real-time multi-color in vivo SWIR imaging systems employing high-power excitation sources in combination with state of the art InGaAs SWIR detectors and SWIR illuminated fluorescent polypeptide.

Abstract: The present invention contemplates methods for the generation of human antigen-specific T lymphocytes. The methods employ MHC class-II targeting signals fused to an antigen or fragment thereof to obtain MHC class presentation of RNA coded proteins. Accordingly, the present invention concerns expression vectors comprising MHC class-II targeting signal and at least one antigen or fragment thereof and its use for the in vitro generation of antigen-specific T lymphocytes. T cell clones and T cell receptors (TCRs) specific for tumor antigens or viral antigens are also described.

Abstract: The present invention contemplates dendritic cell compositions. The dentritic cell compositions employ MHC class-II targeting signals fused to an antigen or fragment thereof to obtain MHC II presentation of the antigen or fragment thereof. In particular, the invention refers to a dendritic cell vaccine comprising dendritic cells expressing a MHC class-II targeting signal fused to an antigen or fragment thereof. Dendritic cell vaccines for the stimulation of an immune response against melanoma-associated antigen are also described.

Abstract: The present invention relates to a food composition and a pharmaceutical comprising D-tryptophan. The present invention further relates to D-tryptophan for use in the treatment, prevention or amelioration of a diseases associated with Treg or TH2 cells, such as allergy and in particular asthma.

Abstract: The invention relates to compounds which are suitable for the treatment of cancer, an immune disease, Parkinson's disease, Cardiac Hypertrophy or Type-2 diabetes and to pharmaceutical compositions containing such compounds. The invention further relates to a kit of parts comprising such compounds.

Abstract: The invention relates to a device (100) and a corresponding method for thermoacoustic sensing, in particular thermoacoustic imaging, the device (100) comprising: a) an irradiation unit (10) configured to generate electromagnetic and/or particle energy exhibiting a first modulation, the first modulation comprising at least one frequency and to continuously emit the energy towards a target (1), whereby acoustic waves are continuously generated in the target, the acoustic waves exhibiting a second modulation, the second modulation comprising the at least one frequency and/or a harmonic frequency of the at least one frequency; b) a detection unit (20) configured to simultaneously detect the acoustic waves exhibiting the second modulation while the energy exhibiting the first modulation is being continuously emitted towards the target (1); and c) a processing unit (30) configured to determine at least one thermoacoustic value of an amplitude and/or a phase of the second modulation of the acoustic waves at the at l

Abstract: The invention includes a device and a method for hybrid optoacoustic and ultrasonographic imaging of an object. The device comprises: an irradiation unit configured to irradiate the object with electromagnetic radiation; first transducer elements configured to detect ultrasound waves generated in the object upon irradiating the object with the electromagnetic radiation; second transducer elements configured to detect ultrasound waves reflected and/or transmitted by the object; a surface comprising at least one first surface segment, on which the first transducer elements are arranged, and at least one second surface segment, on which the second transducer elements are arranged. The first surface segment and/or the second surface segment have a curved shape. The first transducer elements have a first size and pitch and second transducer elements have a second size and pitch, wherein the first pitch and second pitch are different and/or the first size and second size are different.

Abstract: The present invention relates to a polypeptide comprising (a) a first set of six complementarity determining regions (CDRs) configured to bind a first antigen; and (b) (ba) a second set of six CDRs configured to bind a second antigen; or (bb) a ligand capable of binding to a second antigen; wherein (i) said first antigen is selected from Hepatitis B virus (HBV) small surface antigen; HBV medium surface antigen; and HBV large surface antigen; and (ii) said second antigen is selected from surface antigens presented by immune effector cells such as natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). Also provided are compositions for use in a method of treating or preventing HBV infection and/or a condition caused by said HBV infection, said condition caused by said HBV infection being selected from liver cirrhosis and hepatocellular carcinoma.

Abstract: The present invention relates to spiropyrazine compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.

Abstract: The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding the same, a T cell expressing the TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing the tumor-associated antigen.

Abstract: The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.